Download Files:
Products Details
Product Description
– Cefozopran (SCE-2787) is a semi-synthetic, parenteral, fourth-generation cephalosporin. Cefozopran, an antibiotic, has a broad spectrum of antibacterial activity, inhibiting most of the gram-negative and gram-positive organisms[1][2].
Web ID
– HY-B0771
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C19H17N9O5S2
References
– [1]Sato T, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer. 2008;51(6):774-777.|[2]Iizawa Y, et al. Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice. Antimicrob Agents Chemother. 1993;37(1):100-105.
CAS Number
– 113359-04-9
Molecular Weight
– 515.53
SMILES
– [O-]C(C(N1[C@@]2([H])[C@H](NC(/C(C3=NSC(N)=N3)=NOC)=O)C1=O)=C(CS2)C[N+]4=C(C=CC=N5)N5C=C4)=O
Clinical Information
– Launched
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– Antibiotic;Bacterial
Isoform
– β-lactam
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
